Asia-Pacific electrophysiology (EP) market, is set to experience rapid growth in value over the coming years, climbing from approximately USD XX billion in 2016 to USD XX billion by 2022, at a CAGR of XX%. The Asia-Pacific electrophysiology (EP) market consists of ablation catheters, diagnostic catheters and lab systems. Asia-Pacific shows very potential market due to increasing technological innovations, and increasing per capita income and growing economy.
The growth of the Asia- Pacific Electrophysiology market is driven by several factors, the most important of which is the technological innovations. Technological innovations and advancements have led to the introduction of new products. The other factors promoting the growth of the market are increasing incidences of chronic diseases, ease of use and interpretation of medical devices.
Restraints and Opportunities
Factors constraining the growth of the market include reimbursement issues, high cost of the medical devices. Emerging economies, Public awareness for cardiac disease are the major opportunities in the market.
The report segments the market by types and by geography. On the basis of type, the market is classified into electrophysiology monitoring devices and treatment devices. Regionally, the market is segmented into India, China, Japan, South Korea, Australia and Rest of APAC.
Some of the key players in this market include –
Major companies discussed in this report are Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific, GE Healthcare, Johnson & Johnson, Medtronic Inc., Microport.
What makes our report unique?
An extensive research study on the Electrophysiology market, and its entire ecosystem, describes the market trends, drivers, restraints and opportunities of the wearable electronics.
We provide the longest segmentation of the market based on products, technology, components, form factor, products application, industry verticals, and geography.
This report gives a bird eye-view of the market competitive landscape which includes mergers & acquisitions, collaborations, new product launches and key players in the market.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Degree of Competition
5.2.4 Threat of Substitution
5.2.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Non-Invasive Technologies
6.1.2 Increased Survival Rates
6.1.3 Enhanced Accuracy and Speed of Diagnosis
6.1.4 Streamlined Drug Delivery Process
6.1.5 Helps in FDA Approval of Drugs
6.1.6 Boost in Government and Private Funds for Biomarkers Discovery
6.2 Market Restraints
6.2.1 High Cost of Diagnosis
6.2.2 Reimbursement Issues
6.2.3 Need for Immediate Processing
6.3 Market Opportunities
6.3.1 Genetics-Based In-Vitro Diagnostics
6.3.2 Research and Developments
6.4 Key Challenges
6.4.1 Discovery of Novel Biomarkers
6.4.2 Regulatory and Reimbursement Issues
6.4.3 Translational Genetics
7. Market Segmentation
7.1 By Disease Type
7.1.1 Prostate Cancer
7.1.2 Breast Cancer
7.1.3 Lung Cancer
7.1.4 Colorectal Cancer
7.1.5 Cervical Cancer
7.2 By Applications
7.2.1 Risk Assessment
7.2.2 Development of Molecular Diagnostics
7.2.3 Disease Diagnosis
7.2.4 Drug Discovery and Development
7.2.5 Drug Formulation
7.3 By Services
7.3.1 Sample Preparation
7.3.2 Assay Development
7.3.3 Biomarkers Validation and Testing
7.4 By Type
7.4.1 Protein Biomarkers
7.4.2 Genetic Biomarkers
7.4.3 Others (Cell, Viral and Carbohydrate Biomarkers)
7.5 By Profiling Technologies
7.5.1 Omics Technologies
7.5.2 Imaging Technologies
184.108.40.206 Immunohistochemical (IHC) Tests
220.127.116.11 Flow Cytometry
18.104.22.168 DNA Microarrays
7.5.6 Ivd Multivariate Index Assays
8. Segmentation by Geography
8.1.4 Australia & New Zealand
8.1.5 South Korea
8.1.6 Rest of Asia-Pacific
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Abbott Laboratories
10.2 Affymetrix Inc.
10.3 Agilent Technologies
10.4 Gen-Probe Inc.
10.5 Hologic Inc
10.6 Roche Diagnostics Corp.
10.8 Ambry Genetics
10.9 Astex Pharmaceuticals
10.10 Atossa Genetics
10.13 Celera Corporation (Quest Diagnostics)
10.14 Celldex Therapeutics
10.15 Decode Genetics (Amgen)
10.16 Foundation Medicine
11. Future Outlook of the Market